ReviewClinical rheumatology2018
The role of gut microbiota in the pathogenesis of rheumatic diseases.
Review in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05291299 (Anti-Inflammatory Dietary Intervention for Rheumatoid Arthritis), which is not on this map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-Inflammatory Dietary Intervention for Rheumatoid Arthritis
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Molecular mechanisms and risk factors in rheumatoid arthritis: a comprehensive review.Inflammopharmacology · 2026Pooled it
- Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC medicine · 2024Pooled it
- Gut microbiota and Sjögren's syndrome: a two-sample Mendelian randomization study.Frontiers in immunology · 2023Pooled it
- Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies.EBioMedicine · 2022Pooled it
- Association between a gut microbiota-targeted dietary index and osteoarthritis/rheumatoid arthritis: a cross-sectional study.Clinics (Sao Paulo, Brazil) · 2026Article
- Mucosal-Associated Invariant T Cells in Rheumatic Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2026Review
- Muscle relaxant use and the associated risk of Sjögren's syndrome and dry eye disease (including keratoconjunctivitis sicca) in patients with ankylosing spondylitis: a population-based cohort study.Therapeutic advances in drug safety · 2026Article
- Acupuncture treatment for Sjögren's syndrome: a narrative review on mechanism of treatment and clinical application.Frontiers in immunology · 2026Review
- Aryl Hydrocarbon Receptor in Health and Disease.MedComm · 2025Review
- Microbiome impacts surgical outcomes- comparison of gut microbiome dysbiosis in patients undergoing lumbar microdiscectomy: results from the MISO pilot study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
- The Role of Methyl Canthin-6-one-2-carboxylate in Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis Treatment.Current issues in molecular biology · 2025Review
- Microbiome-based therapeutics for ocular diseases.Clinical & experimental optometry · 2025Review
- Article
- Exploring the Gut Microbiome and Metabolome in Individuals with Alopecia Areata Disease.Nutrients · 2024Article
- Review
- Adherence to dietary guidelines, and the risk of developing rheumatoid arthritis: results from a nested case-control study.Rheumatology (Oxford, England) · 2024Article
- The gut homeostasis-immune system axis: novel insights into rheumatoid arthritis pathogenesis and treatment.Frontiers in immunology · 2024Review
- Rheumatic diseases and gut microbiota publications in 2002-2022: a Scopus‑based bibliometric analysis.Rheumatology international · 2023Article
- Insights into Microbiota in Sjögren's Syndrome.Medicina (Kaunas, Lithuania) · 2023Review
- The Integral Role of Diets Including Natural Products to Manage Rheumatoid Arthritis: A Narrative Review.Current issues in molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Rheumatic diseases refer to many diseases with a loss of immune self-tolerance, leading to a chronic inflammation, degeneration, or metabolic derangement in multiple organs or tissues. The cause of rheumatic diseases remains to be elucidated, though both environmental and genetic factors are required for the development of rheumatic diseases. Over the past decades, emerging studies suggested that alteration of intestinal microbiota, known as gut dysbiosis, contributed to the occurrence or development of a range of rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, and Sjogren's syndrome, through profoundly affecting the balance between pro- and anti-inflammatory immune responses. In this article, we discussed the role of gut microbiota in the pathogenesis of rheumatic diseases based on a large number of experimental and clinical materials, thereby providing a new insight for microbiota-targeted therapies to prevent or cure rheumatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.